相关临床试验
9
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
6
66.7%
招募中
3
33.3%
暂无批准数据
- Sidra Medicine, a Qatar Foundation member, has launched a new specialized Microbiome Service providing advanced microbiome testing and analysis for precision medicine. - The private-paid service targets academic and industry investigators, supporting research into the human microbiome's role in health and disease across a range of conditions. - The service combines cutting-edge sequencing technologies with multidisciplinary research expertise to aid diagnosis, treatment strategies, and disease prevention. - Sidra Medicine will also host the second MENA Microbiome Conference from October 17 to 18, reinforcing Qatar's position as a regional hub for scientific innovation.
- Sidra Medicine has been qualified by Vertex Pharmaceuticals to administer Casgevy, the world's first approved CRISPR/Cas9 gene therapy, making it the first hospital in Qatar to offer this treatment. - The therapy is available for patients aged 12 years and older with transfusion-dependent beta thalassemia and severe sickle cell disease, offering potential functional cure through one-time treatment. - Sidra Medicine currently follows approximately 150 to 200 children in Qatar diagnosed with thalassemia and sickle cell disease, with the therapy reserved for the most severe cases. - The hospital has onboarded its first patient for assessment, marking a significant milestone in Qatar's position as a regional leader in precision medicine.
- Rady Children's Institute for Genomic Medicine announced a collaboration with Sidra Medicine in Qatar to implement the BeginNGS genome-based newborn screening program internationally. - The partnership aims to screen newborns for over 1,000 treatable genetic disorders, building on Qatar's existing NOOR project for large-scale newborn genome screening. - BeginNGS technology reduces false positives by 97 percent and benefits one in 13 infants, currently screening for 511 severe childhood genetic diseases across multiple US hospitals. - The collaboration supports the program's goal of implementing screening for 1,000 diseases in at least 10 countries by 2030.
• Sidra Medicine has successfully conducted Qatar's first industry-sponsored pharmaceutical trial for pediatric congenital hyperinsulinism, marking a significant advancement in treating this rare condition. • The Phase 3 sunRIZE trial, led by Rezolute, aims to evaluate a new, safer, and non-invasive treatment option, potentially reducing the need for invasive pancreatic surgery in affected children. • The trial focuses on clinical trials that will benefit children in the Arab region, particularly those with rare diseases that lack effective treatment, offering new hope for patients and families. • Sidra Medicine was selected as one of 22 leading centers worldwide to participate in the sunRIZE Phase 3 clinical trial, highlighting its growing prominence in pediatric endocrinology.
- Sidra Medicine initiates a clinical trials program focusing on rare and complex diseases affecting children in the Arab region, addressing a significant data gap. - The program aims to provide personalized treatment options, particularly for children with genetic ancestries unique to the Middle East, who are often overlooked in drug development. - Sidra Medicine's trials will cover conditions like Congenital Hyperinsulinism, Spinal Muscular Atrophy, and pediatric cancers, utilizing medicines and procedures approved for adults but not yet for children. - The initiative includes rigorous ethical reviews and partnerships with global institutions and pharmaceutical companies, positioning Sidra Medicine as a regional leader in pediatric clinical research.
